Vinorelbine, doxorubicin, and prednisone in androgen‐independent prostate cancer

Abstract

Background To examine the practical applicability, internal consistency, and validity of the Bt‐DUX, a disease‐specific Health Related Quality of Life (HRQoL) instrument. The Bt‐Dux was developed to examine patients' individual values of their life after a malignant bone tumor of the lower extremity at four domains (cosmetic, social, emotional, and functional). Procedure Patients were eligible for this cross‐sectional, multicenter study if they underwent surgery for a malignant tumor of the leg in a period ranging between 12 and 60 months before the recruitment. Assessments included: Bt‐DUX, Toronto Extremity Salvage Score (TESS) Short Form (SF)‐36, TNO‐AZL Questionnaire for Adult's Quality of Life (TAAQOL), and TNO‐AZL Children's Quality of Life Questionnaire (TACQOL). Results Seventy‐two patients (35 male, 37 female), mean age 17 (SD 4) years were included. Limb sparing surgery took place in 32 patients and ablative surgery in 40 patients. The Bt‐DUX was completed in less than 5 min and easy to comprehend. The mean Bt‐DUX score was 69.8 (SD 15.5), with Cronbach's alpha being 0.92. Domain–total correlations ranged between 0.84 and 0.88 (P < 0.01). Correlations between Bt‐DUX Total score and TESS, SF‐36 Physical and Mental Component Summary scales and selected TACQOL and TAAQOL scores were statistically significant (P < 0.05), except for the social scale of the TACQOL. The Bt‐DUX was able to discriminate between patients with higher and lower TESS scores (P < 0.05). Conclusion The Bt‐DUX was found to be a practical and valid instrument. Its added value compared with existing HRQoL measures needs to be further established. Pediatr Blood Cancer 2009;53:348–355. © 2009 Wiley‐Liss, Inc.

Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation

“…Nonetheless, these agents continue to be assessed in clinical trials for prostate cancer as components of chemotherapeutic combinations, in different formulations, and in the form of later generation analogues (39,42). The results of the present study provide a rationale for the inclusion of modulators of Ku70 acetylation in clinical trials that involve these DNA-damaging agents for the treatment of prostate cancer patients.…”

“…chemotherapeutic combinations against prostate cancer (35)(36)(37)(38)(39), their widespread clinical use has been limited by toxicities and lack of definitive survival benefits, particularly compared with recent advances showing improved survival with docetaxel-based strategies (40,41). Nonetheless, these agents continue to be assessed in clinical trials for prostate cancer as components of chemotherapeutic combinations, in different formulations, and in the form of later generation analogues (39,42).…”